で公開中です! 詳しく見る
RDYのアイコン

Dr. Reddy's Laboratories

13.07 USD
+0.17
1.32%
終値時点 更新済み 10月16日 16:00 EDT
1日
1.32%
5日間
3.73%
1か月
11.9%
3か月
2.91%
6か月
0.08%
年初来
-5.7%
1年
-8.09%
5年間
1.08%
10年間
45.06%
 

概要: Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

従業員数: 27,527

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 7.7%
ニュートラル 76.9%
ネガティブ 15.4%
ニュートラル
PRNewsWire
22 日前
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
GlobeNewsWire
24 日前
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ポジティブ
Reuters
29 日前
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
ニュートラル
PRNewsWire
29 日前
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
GlobeNewsWire
先月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
GlobeNewsWire
先月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
PRNewsWire
先月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
GlobeNewsWire
先月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
PRNewsWire
先月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
ニュートラル
GlobeNewsWire
先月
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
価格チャートは Lightweight Charts™ を使用して実装されています